References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. View
2. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. MolNutr Food Res 53: 171-184. View
3. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46: 3040-3052. View
4. vale R, Møller B, Angelsen A, Dahl O, Fossa SD, et al. (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway1980-2007. Cancer Epidemiol 34: 359-367. View
5. Mcleod DG (2003) Hormonal therapy: historical perspective to future directions. Urology. 61: 3-7. View
6. Sethi R, Sanfilippo N (2009) Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. ClinInterv Aging. 4: 259-267. View
7. Miller K, Anderson J, Abrahamsson PA (2009) Treatment of prostate cancer with hormonal therapy in Europe. BJU Int 103: 2-6.
8. Horwich A, Parker C, Kataja V (2008) Prostate cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 19: 45-46. View
9. Palmberg C, Koivisto P, Visakorpi T, Tammela TL (1999) PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 36: 191-196. View
10. Kawakami J, Morales A (2013) Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can UrolAssoc J 7: 226-230. View
11. Ploussard G, Mongiat-Artus P (2013) Triptorelin in the management of prostate cancer. Future Oncol 9: 93-102. View
12. Moretti RM, MonagnaniMarelli M, van Groeninghen JC, Motta M, Limonta P (2003) Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. EndocrRelat Cancer. 10: 161-167. View
13. Smith MR (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. CurrOpinEndocrinol Diabetes Obes 14: 247-254. View
14. Berges R, Bello U (2006) Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 22: 649-655. View
15. Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J et al. (2012) Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis 15: 93-99. View
16. Fowler JE Jr, Gottesman JE, Reid CF, Andriole GL Jr, Soloway MS (2000) Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 164: 730-734.
17. Clinical study report. Comparative testosterone pharmacodynamics and therapeutic efficacy of 1- and 3-month formulations of triptorelinpamoate in patients with advanced prostate cancer. DEB-96-TR1-01 (first phase). Lausanne, Switzerland: Debiopharm SA; 1999.
18. Lepor H (2005) Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 5: 3-12. View
19. Sharifi R. et al. (2002) Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 168: 1001-1004. View
20. Crawford ED, Phillips JM (2011) Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res 3: 201-209. View
21. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence (Review). Cochrane Database Syst. View
22. Jimmy B, Jose J (2011) Patient Medication Adherence: Measures in Daily Practice. Oman Med J 26: 155-159. View
23. World Health Organization. Adherence to Long-term Therapies: Evidence for Action World Health Organization, Geneva; 2003. View
24. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, et al (2008) Medication compliance and persistence: terminology and definitions. Value Health. 11: 44-47. View
25. Balkrishnan R (2005) The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 43: 517-520. View
26. Vrijens B, De Geest S, Hughes D A, Przemyslaw K, Demonceau J, et al. (2012) A new taxonomy for describing and defining adherence to medications. Br J ClinPharmacol. 73: 691-705. View
27. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, et al. (2009) Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 12: 989-995. View
28. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, et al. (2008) An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 46: 1125- 1133. View
29. Hess LM, Raebel MA, Conner DA, Malone DC (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40: 1280-1288. View
30. Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV (2012) Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence. 6: 653-661. View
31. Dupclay L, Eaddy M, Jackson J, Raju A, Shim A (2012) Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence. Patient Prefer Adherence 6: 499-507. View
32. Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, et al. (2012) Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care 35: 2533- 2539. View
33. Vollmer WM, Feldstein A, Smith DH, Dubanoski JP, Waterbury A, et al. (2011) Use of health information technology to improve medication adherence. Am J Manag Care. 17: 79-87. View
34. Ratanawongsa N, Karter AJ, Parker MM, Lyles CR, Heisler M, et al. (2013) Communication and medication refill adherence: the Diabetes Study of Northern California. JAMA Intern Med 173: 210-218. View
35. Kocarnik BM, Liu CF, Wong ES, Perkins M, Maciejewski ML, et al. (2012) Does the presence of a pharmacist in primary care clinics improve diabetes medication adherence? BMC Health Serv Res 12: 391. View
36. Cocohoba JM, Murphy P, Pietrandoni G, Guglielmo BJ (2012) Improved antiretroviral refill adherence in HIV-focused community pharmacies. J Am Pharm Assoc 52: 67-73. View
37. Sharma KP, Taylor TN (2012) Pharmacy effect on adherence to antidiabetic medications. Med Care 50: 685-691. View
38. Gu Q, Zeng F, Patel BV, Tripoli LC (2010) Part D coverage gap and adherence to diabetes medications. Am J Manag Care 16: 911-918. View
39. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15: 728-740. View
40. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE (2011) Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ 89: 632-639. View
41. Gu Q, Zeng F, Patel BV, Tripoli LC (2010) Part D coverage gap and adherence to diabetes medications. Am J Manag Care 16: 911-918.
42. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 15: 728-740.
43. Vollmer WM, Feldstein A, Smith DH, Dubanoski JP, Waterbury A, et al. (2011) Use of health information technology to improve medication adherence. Am J Manag Care. 17: 79-87.
44. Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, et al. (2011) Regional, Geographic, and Ethnic Differences in Medication Adherence Among Adults with Type 2 Diabetes (February). Ann Pharmacother. View
45. Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, et al. (2007) Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 48: 5052-5057. View
46. Hess LM, Raebel MA, Conner DA, Malone DC (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40: 1280-1288.
47. Santoleri F, Sorice P, Lasala R, Rizzo RC, Costantini A (2013) Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLoS One 8: 56813. View
48. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, et al. (2007) A checklist for medication compliance and persistence studies using retrospective database. Value Health 10: 3-12. View
49. WHO Collaborating Centre for Drug Statistics Methodology. (2013) Guidelines for ATC classification and DDD assignment 2012. Oslo. View